Form 4: Alnylam Director Olivier Brandicourt Acquires Stock Options
SEC Form 4
Director Olivier Brandicourt reports the acquisition of stock options in Alnylam Pharmaceuticals.
Summary
- On May 16, 2024, Olivier Brandicourt, a director of Alnylam Pharmaceuticals, acquired 5,228 stock options.
- The exercise price of these options is $151.22.
- The options vest in full on the earlier of May 16, 2025, or the date of retirement or resignation, provided such date occurs no more than 90 days prior to the first anniversary of the grant date.
- Brandicourt also has a power of attorney designating Jeffrey Poulton, Brett Budzinski, Gisele Dion, and Stephen Hall to handle Section 16 reporting obligations.
Sentiment
Score: 6
Explanation: The document is a neutral report of a transaction. The acquisition of stock options by a director is generally viewed as a positive sign, but the document itself is simply a factual disclosure.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance beyond the vesting date of the options.
Industry Context
This filing is a routine disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Comparison to Industry Standards
- Stock option grants are a common component of compensation packages for directors and officers in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical for such grants, aligning with industry standards for incentivizing long-term performance.
Stakeholder Impact
- The acquisition of stock options by a director may have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of transaction: Olivier Brandicourt acquired stock options. |
| 05/16/2025 | Vesting date of the stock options, or earlier upon retirement/resignation under specific conditions. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.